These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20065050)

  • 21. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
    Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model.
    Domán M; Kovács R; Kardos G; Gesztelyi R; Juhász B; Bozó A; Kardos T; Saleh Q; Majoros L
    Curr Drug Deliv; 2016; 13(2):255-64. PubMed ID: 27146910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.
    Wiederhold NP; Grabinski JL; Garcia-Effron G; Perlin DS; Lee SA
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4145-8. PubMed ID: 18794385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
    Hernandez S; López-Ribot JL; Najvar LK; McCarthy DI; Bocanegra R; Graybill JR
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1382-3. PubMed ID: 15047549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.
    Kovács R; Gesztelyi R; Perlin DS; Kardos G; Domán M; Berényi R; Majoros L
    Mycopathologia; 2014 Oct; 178(3-4):197-206. PubMed ID: 25118874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caspofungin-non-susceptible Candida isolates in cancer patients.
    Kofteridis DP; Lewis RE; Kontoyiannis DP
    J Antimicrob Chemother; 2010 Feb; 65(2):293-5. PubMed ID: 20016020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
    Jacobsen MD; Whyte JA; Odds FC
    Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutants of Candida albicans hypersensitive to calcofluor white display susceptibility to antifungal drugs.
    He ZM; Chen J; Li HZ; Luo DQ; Yang W
    Folia Microbiol (Praha); 2010 Mar; 55(2):159-66. PubMed ID: 20490759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
    Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
    Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of
    Yang F; Zhang L; Wakabayashi H; Myers J; Jiang Y; Cao Y; Jimenez-Ortigosa C; Perlin DS; Rustchenko E
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips.
    Siopi M; Tsala M; Siafakas N; Zerva L; Meletiadis J
    J Clin Microbiol; 2015 Nov; 53(11):3654-9. PubMed ID: 26338855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.
    Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
    Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced efficacy of synergistic combinations of antimicrobial peptides with caspofungin versus Candida albicans in insect and murine models of systemic infection.
    MacCallum DM; Desbois AP; Coote PJ
    Eur J Clin Microbiol Infect Dis; 2013 Aug; 32(8):1055-62. PubMed ID: 23572153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology.
    Szilágyi J; Földi R; Bayegan S; Kardos G; Majoros L
    J Chemother; 2012 Feb; 24(1):18-25. PubMed ID: 22546720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms.
    Delattin N; De Brucker K; Vandamme K; Meert E; Marchand A; Chaltin P; Cammue BP; Thevissen K
    J Antimicrob Chemother; 2014 Apr; 69(4):1035-44. PubMed ID: 24284780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of micafungin against biofilms of Candida albicans, Candida glabrata, and Candida parapsilosis at different stages of maturation.
    Prażyńska M; Bogiel T; Gospodarek-Komkowska E
    Folia Microbiol (Praha); 2018 Mar; 63(2):209-216. PubMed ID: 28983822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms.
    Bink A; Kucharíková S; Neirinck B; Vleugels J; Van Dijck P; Cammue BP; Thevissen K
    J Infect Dis; 2012 Dec; 206(11):1790-7. PubMed ID: 22984120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.